Genzyme gears up for Lemtrada EU launch amid stiff MS competition
This article was originally published in Scrip
Executive Summary
The European Commission has approved Genzyme's MS drug Lemtrada (alemtuzumab), making the EU the first launch market for the product, but it will face tough competition from MS drugs already on the market, particularly Biogen Idec's Tysabri (natalizumab).